In contrast, we found that PRDX2 and PRDX4 showed better PFS in all ovarian cancer patients treated with Platin, Taxol, and Taxol+Platin chemotherapy, implying that PRDX2 and PRDX4 predict better prognosis in ovarian cancer patients treated with these three chemotherapeutic drugs. This evidence concerns the gene PRDX2 and ovarian carcinoma.